TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06645418

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: relative Hand grip strength
Description: To perform this study the relative handgrip strength (rHGS) index was used. The rHGSi is defined as the sum of the handgrip strength of both hands divided by body mass index (BMI), and it is considered a better prognostic tool than handgrip strength. rHGS was measured by Jamar hand dynamometer. The Functional Performance was determined by using 3 tests of the Senior Fitness Test (The 30-second chair stand test, the 8-feet Up-and-Go test, and the 2 minutes' Walk Test).

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: relative Hand grip strength
Description: To perform this study the relative handgrip strength (rHGS) index was used. The rHGSi is defined as the sum of the handgrip strength of both hands divided by body mass index (BMI), and it is considered a better prognostic tool than handgrip strength. rHGS was measured by Jamar hand dynamometer. The Functional Performance was determined by using 3 tests of the Senior Fitness Test (The 30-second chair stand test, the 8-feet Up-and-Go test, and the 2 minutes' Walk Test).

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: senior fitness test
Description: The Functional Performance was determined by using 3 tests of the Senior Fitness Test (The 30-second chair stand test, the 8-feet Up-and-Go test, and the 2 minutes' Walk Test).

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: senior fitness test
Description: The Functional Performance was determined by using 3 tests of the Senior Fitness Test (The 30-second chair stand test, the 8-feet Up-and-Go test, and the 2 minutes' Walk Test).
Study: NCT06443632

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sleep Adjustment
Description: (1) Establishing a sleep schedule with early bedtime and wake-up times; (2) Establishing a consistent bedtime routine based on the child's preferences, such as wearing a sleep sack, providing soothing touch before sleep, offering a pacifier, using white noise, or playing sleep-inducing music; (3) Setting a fixed afternoon radiotherapy time each day and familiarizing the child with the radiotherapy environment beforehand; (4) Engaging the child in stimulating activities like watching videos, playing with toys, snacking, or outdoor activities to keep them awake from morning until 2 PM before radiotherapy; (5) Ensuring the child reaches deep sleep; (6) Completing the radiotherapy plan.
Study: NCT06602817

Intervention type: OTHER
Intervention: Exposure: prone position
Description: Exposure: surgery in prone position

Intervention type: OTHER
Intervention: Exposure: Supine position
Description: Exposure: Surgery in supine position
Study: NCT06569355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VCT220
Description: A small molecule GLP-1R agonist tablet, orally administration, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VCT220
Description: A small molecule GLP-1R agonist tablet, orally administration, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VCT220
Description: A small molecule GLP-1R agonist tablet, orally administration, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VCT220
Description: A small molecule GLP-1R agonist tablet, orally administration, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablet
Study: NCT06569810

Intervention type: DEVICE
Intervention: Repeated Low-Level Red Light (RLRL) therapy
Description: In our study, we do not implement any interventions; rather, we collect follow-up information from patients who, due to insufficient response to traditional myopia control therapies, have transitioned to Repeated Low-Level Red Light (RLRL) therapy. The data gathered will reflect treatment patterns as per the approved indications for RLRL therapy, where subjects may have undergone treatment sessions twice daily, each lasting for 3 minutes with a minimum interval of 4 hours between sessions. Our analysis will focus on the real-world outcomes, specifically evaluating the proportion of participants who have achieved effective myopia control (defined as AL elongation of less than 0.1mm per year or SER progression of less than 0.25 diopter per year) after 12 months of documented RLRL therapy use among the collected data from eligible subjects.
Study: NCT06570005

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water Quality Assurance Fund
Description: * At the water system level: Written legal agreements between water systems, centralized laboratories, and the organization facilitating the Assurance Fund will provide water systems with regular water quality testing and provide laboratories a guarantee of payments if water systems fail to pay for testing services on time (for up to three concurrent unpaid invoices). Regular debrief meetings will be held with water operators and local government authorities to discuss test results and water treatment options, and to encourage water systems to share water quality information with their consumers. Technical guidance to improve water treatment will be provided, if requested by water system operators or local government authorities.~* At the community level: Community engagement, primarily at the onset, to inform the community about the water quality testing program and answer questions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water Quality Assurance Fund
Description: * At the water system level: Written legal agreements between water systems, centralized laboratories, and the organization facilitating the Assurance Fund will provide water systems with regular water quality testing and provide laboratories a guarantee of payments if water systems fail to pay for testing services on time (for up to three concurrent unpaid invoices). Regular debrief meetings will be held with water operators and local government authorities to discuss test results and water treatment options, and to encourage water systems to share water quality information with their consumers. Technical guidance to improve water treatment will be provided, if requested by water system operators or local government authorities.~* At the community level: Community engagement, primarily at the onset, to inform the community about the water quality testing program and answer questions.
Study: NCT04819854

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EP395
Description: capsule for oral treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: capsule for oral treatment
Study: NCT06565247

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]PSMA-PET
Description: Pre-surgical imaging using \[18F\]PSMA-PET at Umea University Hospital, 3.5 MBq/kg, i.v. injection.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI sequences optimized for prostate cancer examinations
Description: T2-WI, T1-WI, DCE and DWI at Umea University Hospital and at Skåne University Hospital
Study: NCT06586112

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ESK-001
Description: ESK-001

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apremilast
Description: Apremilast

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT06607406

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Accelerated radiotherapy
Description: 6 fractions per week, BID fractions one day per week

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Conventional radiotherapy
Description: 5 fractions per week, daily M-F
Study: NCT06594770

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Atraumatic Restorative Treatment
Description: A sharp excavator will be used to remove soft demineralized carious tissue from the patient\&#39;s primary molar 2-The molar will then be restored with capsulated Glass Ionomer in accordance to ART procedure.~3-Each capsule will be mixed for ten seconds and used for restoring teeth isolated by cotton rolls.~4-After the cement is cured, excess material will be removed with an excavator and a carver.~5-The occlusion will be tested for interferences with carbon paper. A layer of varnish coat will be applied to the surface and light-cured for 20 seconds .

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hall technique
Description: The procedure involves assessing the occlusion, contact points, and tooth shape. If contact points are present, orthodontic separators will be placed between the primary molars to create space for crown fitting, with the child seated upright to maintain airway safety. After 3 to 5 days, the separators will be removed, and loose plaque and debris will be cleared.~The correct crown size will be selected, ensuring it doesn't impinge on adjacent teeth, and will be filled with glass ionomer cement. The child will be instructed to bite down for two minutes to ensure proper seating. Excess cement will be removed, and contacts will be flossed. Any initial occlusal discrepancies are expected to resolve within weeks.
Study: NCT06303453

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balance exercises
Description: Balance exercises includes active movements (flexion, extension, abduction, adduction) of one upper extremity and lower extremity, trunk movements (bending forward and rotation), raising heel, raising toes and raising heel. Every move in each session will be hold for 30 seconds. The part B comprises of training i.e., holding positions in standing posture which include moving the ball up and down in a straight line with two upper extremities, moving the ball up and down in an oblique line with two upper extremities, moving the ball forward and backward with left and right lower extremities, moving the ball laterally with left and right lower extremities, throwing the ball against the wall with hand and throwing the ball against the wall with foot.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resisted exercises
Description: The resistance training protocol include shoulder flexion and extension with 1 kg weight, shoulder pulley with 2 kg weight, arm curls with 1 kg weight, wall push-ups, bridging, hip abduction and adduction against resistance band, knee extensions and flexion in sitting position with resistance applied by contralateral limb, knee adduction and abduction with resistance band, mini squats, strengthening exercise for toes flexor and extensor (22), resisted inversion and eversion and straight leg raise (SLR) with 1 kg ankle weight (10).~Every move in each session comprises of 2 sets of 3 reps each and 1 set will be added at 4th and 8th week.
Study: NCT04758533

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AloCELYVIR
Description: Mesenchymal allogenic cells + ICOVIR-5: 500.000 cells/kg
Study: NCT04823689

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: reductions
Description: Two reduction techniques are compared: dorsal decubitus and ventral decubitus reduction. The dorsal decubitus reduction consists in placing the patient in the dorsal position and achieving reduction by traction maneuvers on the luxated upper limb. This maneuver generally requires procedural sedation. A mild traction of the traumatized limb in the axis is performed, with slight external rotation and progressive abduction. In the absence of reduction at this stage, this gesture is completed by a flexion adduction of the limb. A counterweight is then made by a rolled sheet and passed under the armpit of the patient.~The ventral decubitus reduction consists in placing the patient in the ventral position. The luxated limb is positioned in pendulum and the line of contact with the stretcher must pass through the mid-clavicular line. The humeral head is brought to the scapula.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: reductions
Description: Two reduction techniques are compared: dorsal decubitus and ventral decubitus reduction. The dorsal decubitus reduction consists in placing the patient in the dorsal position and achieving reduction by traction maneuvers on the luxated upper limb. This maneuver generally requires procedural sedation. A mild traction of the traumatized limb in the axis is performed, with slight external rotation and progressive abduction. In the absence of reduction at this stage, this gesture is completed by a flexion adduction of the limb. A counterweight is then made by a rolled sheet and passed under the armpit of the patient.~The ventral decubitus reduction consists in placing the patient in the ventral position. The luxated limb is positioned in pendulum and the line of contact with the stretcher must pass through the mid-clavicular line. The humeral head is brought to the scapula.
Study: NCT05601869

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RECOVER Prosthetic Ankle-Feet System
Description: The RECOVER prosthetic ankle-feet system includes a single prosthetic ankle joint that can be easily attached to 3D printed feet. The feet are designed to fit specifically within different footwear.
Study: NCT04039464

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mono-Therapy with Sildenafil
Description: The subjects will be randomized to receive sildenafil alone and will undergo study procedures as outlined in section 1.3. There will not be a placebo group.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duo-Therapy with Sildenafil + Bosentan
Description: The subjects will be randomized to receive combination up-front therapy sildenafil and bosentan and will undergo study procedures as outlined in section 1.3. There will not be a placebo group.
Study: NCT06288152

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Thiosulfate
Description: 0.15 mL administered
Study: NCT05497934

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycerol
Description: In this study, 99.5% pure glycerol will be used as an optical clearing agent. The glycerol will be applied topically to the tympanic membrane.
Study: NCT06068608

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: single,intramuscular injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VariZIG
Description: a single dose of VARIZIG 625 IU,intramuscular injection
Study: NCT03870360

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HOLA Component 1
Description: At week 1 and week 8 participants will meet individually with Community Health Worker (CHW) for 30 minutes for a manualized social and physical activation session.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HOLA Component 2
Description: A CHW led 45 minute (10 minutes of stretching and warm up, followed by 30 minutes of walking with a 5 minute cool down) group walk session of six participants at a time done 3 times a week that utilized interval training that slowly gradually increases in intensity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HOLA Component 3
Description: A CHW led pleasant event discussion, asking each participant to identify a pleasant event. This task is done in conjunction with the cool down of HOLA 2.
Study: NCT05659134

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Alfredson protocol
Description: Alfredson eccentric therapeutical protocol.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Silbernagel protocol
Description: Silbernagel concentric-eccentric protocol.
Study: NCT05069233

Intervention type: OTHER
Intervention: UGI+SB
Description: Patients who underwent combined upper digestive tract and small intestine examination under MCE.
Study: NCT06516198

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Auricular Acupressure
Description: Seeds will be placed during the clinic visit by the acupuncturist or the research associate according to the group the patient was assigned to. The care partner will observe the placement. A photograph of the seed placement will be taken and given to the care partner and to the patient after the relevant points are labeled by number or letter. The method of pressing is demonstrated for 1 one of the seeds, the care partner practices pressing on 2 other seeds, and the patient practices pressing on the remaining 2 seeds. Pressing consists of applying pressure, gradually increasing the pressure until the patient expresses discomfort, and maintaining that pressure until 2 minutes have passed. After pressing has been performed for each seed, the seeds are removed in clinic prior to clinic discharge.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Auricular Acupressure
Description: Seeds will be placed during the clinic visit by the acupuncturist or the research associate according to the group the patient was assigned to. The care partner will observe the placement. A photograph of the seed placement will be taken and given to the care partner and to the patient after the relevant points are labeled by number or letter. The method of pressing is demonstrated for 1 one of the seeds, the care partner practices pressing on 2 other seeds, and the patient practices pressing on the remaining 2 seeds. Pressing consists of applying pressure, gradually increasing the pressure until the patient expresses discomfort, and maintaining that pressure until 2 minutes have passed. After pressing has been performed for each seed, the seeds are removed in clinic prior to clinic discharge.
Study: NCT06547346

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Alfamino Junior
Description: To recruit 15 children and evaluate the acceptability (including gastrointestinal tolerance), palatability and compliance of a hypoallergenic amino acid powdered formula (neutral and vanilla flavours) with HMO's for the dietary management of presumed cows' milk allergy, multiple food protein allergies and other conditions where an amino acid formula is recommended in children ≥1 year of age.
Study: NCT06547632

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ClearPetra Ureteral access sheath
Description: Patients will be randomly assigned (1:1) to vacuum-assisted (ClearPetra) or traditional approach group for retrograde intrarenal surgery according to standard of care.
Study: NCT05352724

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hydration drink
Description: Intake of the different hydrating drinks for 4 weeks 3 times a week during sports practice

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Hydration drink
Description: Intake of the different hydrating drinks for 4 weeks 3 times a week during sports practice

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Hydration drink
Description: Intake of the different hydrating drinks for 4 weeks 3 times a week during sports practice
Study: NCT06674174

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: lower limb strength training
Description: Experimental group will receive lower limb strength training treatment for three days a week and each session will last for an hour for 3 consecutivemonths. Measurement will be recorder pre-treatment and post treatment of both groupsat baseline,3rd, and 6th week.
Study: NCT03870360

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HOLA Component 4
Description: One booster walking session twice a month for six months post intervention for reinforcement, then one booster walking session a month for eighteen months.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy lifestyles education program
Description: Biweekly telephone check in calls for the first 16 weeks followed by monthly check in calls during the two year follow up period.
Study: NCT06674174

Intervention type: OTHER
Group type: OTHER
Intervention: endurance training
Description: Control group will receive endurance training, treatment for three days a week and each session will last for an hour for 3 consecutivemonths. Measurement will be recorder pre-treatment and post treatment of both groupsat baseline,3rd, and 6th week.
Study: NCT06444451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlitelimab
Description: Pharmaceutical form: Injection solution Route of administration: SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlitelimab
Description: Pharmaceutical form: Injection solution Route of administration: SC injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: Injection solution Route of administration: SC injection
Study: NCT06683846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivocizumab
Description: Administered via intravenous (IV) infusion
Study: NCT06625710

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GV1001
Description: Lyophilized peptide from hTERT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GV1001
Description: Lyophilized peptide from hTERT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GV1001
Description: Lyophilized peptide from hTERT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GV1001
Description: Lyophilized peptide from hTERT
Study: NCT06292104

Intervention type: DIAGNOSTIC_TEST
Intervention: multimodal diagnostic testing
Description: Serological testing, cardiac MRI, skin biopsy, cardiovascular testing, blood volume measurements
Study: NCT06625710

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GV1001
Description: Lyophilized peptide from hTERT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GV1001
Description: Lyophilized peptide from hTERT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GV1001
Description: Lyophilized peptide from hTERT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9 % Normal Saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9 % Normal Saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9 % Normal Saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9 % Normal Saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9 % Normal Saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9 % Normal Saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9 % Normal Saline